Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GammaDelta Therapeutics

https://gammadeltatx.com/

Latest From GammaDelta Therapeutics

Asia Deal Watch: I-Mab Partners With Sinopharm As It Readies First Regulatory Filing

I-Mab sets commercial plans with Sinopharm for felzartamab in multiple myeloma. Legochem and Antengene team up on antibody-drug conjugates, Luoxin licenses respiratory drug from Marinomed.

Deal Watch Business Strategies

Takeda Buys Out Partner GammaDelta In Cell Therapy Push

Japanese major buys out existing cancer cell therapy research partner, exercising an exclusive option dating back to a 2017 collaboration and expanding its immuno-oncology ambitions and pipeline.

M & A ImmunoOncology

Abingworth Closes 12th Life Sciences Fund ABV VII At $315M

European biotechs are likely to be the big winner as transatlantic VC Abingworth closes its latest fund, Abingworth Ventures VII (ABV VII), at $315m, exceeding its $300m target.

Commercial Financing

Appointments: Sanofi, Celgene, TeGenix, Allogene, Aimmune, TikoMed and Ionis Announce Changes At The Top

This week's appointments include a new CFO at Sanofi,  a new general counsel at Celgene plus new hires at TiGenix, Allogene Therapeutics, Aimmune Therapeutics, TikoMed and Ionis Pharmaceuticals, among others.

Executive Changes BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Other Names / Subsidiaries
    • Adaptate Biotherapeutics
    • Lymphact – Lymphocyte Activation Technologies, S.A.
UsernamePublicRestriction

Register